分享好友 资讯首页 频道列表

FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025

2025-06-16 09:1212410

FDA is expected to notify Innoviva Specialty Therapeutics regarding its decision to conduct an Advisory Committee Meeting in the Day 74 letter

If approved, zoliflodacin would be the first new antibiotic for treating gonorrhea in decades

WALTHAM, Mass. & GENEVA--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for zoliflodacin, an investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in adults and pediatric patients 12 years and older. The FDA assigned a target action date of December 15, 2025 under the Prescription Drug User-Fee Act (PDUFA). It is expected the FDA will notify Innoviva Specialty Therapeutics regarding the FDA’s decision to conduct an Advisory Committee Meeting in the Day 74 letter. If approved, zoliflodacin would be the first new antibiotic for treating gonorrhea in decades.

The U.S. FDA has granted zoliflodacin a Qualified Infectious Disease Product (QIDP) designation. This designation allows it to benefit from FDA Priority Review, and Extended Market Exclusivity.

Entasis Therapeutics, Inc., the legal NDA holder and affiliate of Innoviva Specialty Therapeutics, Inc., retains the commercial rights for zoliflodacin in the major markets in North America, Europe, and Asia-Pacific. GARDP retains the right to register and commercialize the product in more than three-quarters of the world’s countries, including all low-income countries, most middle-income countries, and several high-income countries. GARDP is committed to working with its partners and local health authorities in markets where zoliflodacin receives regulatory approval to help remove access barriers to ensure treatment is available to address unmet medical needs while ensuring appropriate and sustainable use.

About Uncomplicated Gonorrhea

With more than 82 million new gonorrhea infections occurring globally each year, gonorrhea is the second most common bacterial sexually transmitted infection (STI), affecting both men and women, which, if left untreated, can result in serious and permanent health consequences.

With the rise and spread of drug-resistant infections, the World Health Organization (WHO) has identified antimicrobial resistance (AMR) as one of the ten most critical global threats to public health. The bacterium Neisseria gonorrhoeae, which causes gonorrhea, has progressively developed resistance to most classes of antibiotics used to treat these infections, including ceftriaxone, a widely used intramuscular injection that was first made available in 1984.

About Zoliflodacin

Zoliflodacin is an investigational first-in-class antibacterial that is administered in a single oral dose for the treatment of uncomplicated gonorrhea. The oral route of administration simplifies treatment by providing a convenient option for patients unable to receive an intramuscular injection. Zoliflodacin has a unique mechanism of action, inhibiting a crucial bacterial enzyme called type II topoisomerase, which is essential for bacterial function and reproduction. In in vitro studies, zoliflodacin demonstrated activity against multidrug-resistant strains of Neisseria gonorrhoeae, including those resistant to ceftriaxone and azithromycin, with no cross-resistance to other antibiotics. In a pivotal Phase 3 clinical trial, zoliflodacin demonstrated non-inferiority in achieving microbiological cure at the urogenital site of infection with a single oral dose of zoliflodacin compared to a treatment regimen of a single intramuscular injection of 500mg ceftriaxone followed by 1g of oral azithromycin. The Phase 3 study found that zoliflodacin was generally well-tolerated, with no serious adverse events or deaths reported during the trial.

About GARDP

The Global Antibiotic Research & Development Partnership (GARDP) is a not-for-profit global health organization driven to protect people from the rise and spread of drug-resistant infections, one of the biggest threats to us all. By forging the public and private partnerships that matter, we develop and make accessible antibiotic treatments for people who need them. Vital support for our work comes from the governments of Canada, Germany, Japan, Monaco, the Netherlands, Switzerland, the United Kingdom, the Canton of Geneva, the European Union, as well as the Gates Foundation, Global Health EDCTP3, GSK, the RIGHT Foundation, the South African Medical Research Council (SAMRC) and Wellcome.

About Innoviva

Innoviva is a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets. Innoviva’s royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (“GSK”). Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva’s other innovative healthcare assets include infectious disease and critical care assets stemming from acquisitions of Entasis Therapeutics, including XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex and the investigational zoliflodacin currently being developed for the treatment of uncomplicated gonorrhea, and La Jolla Pharmaceutical Company, including GIAPREZA® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA® (eravacycline) for the treatment of complicated intra-abdominal infections in adults. Innoviva also markets ZEVTERA® (ceftobiprole), an advanced-generation cephalosporin antibiotic, in the U.S. through an exclusive license from Basilea Pharmaceutica International Ltd, Allschwil. For more information about Innoviva, go to www.innoviva.com. For information about Innoviva Specialty Therapeutics, go to www.innovivaSpecialtytherapeutics.com.

ANORO®, RELVAR® and BREO® are trademarks of the GSK group of companies. ZEVTERA® is a trademark of Basilea Pharmaceutica Ltd, Allschwil.

 

Contacts

Media
Innoviva Specialty Therapeutics
David Patti
David.patti@inva.com
+1.908.421.5971

GARDP
Duncan Graham-Rowe
dgrahamrowe@gardp.org
+44 7966 413623

Investors
Argot Partners
innoviva@argotpartners.com
+1.212.600.1902

反对 0
举报 0
收藏 0
打赏 0
评论 0
Omdia:BOE有望在2025年成为苹果MacBook显示面板的最大供应商
伦敦--(美国商业资讯)-- Omdia的 “平板电脑和笔记本显示面板及OEM研究服务”最新分析显示,2025年京东方(BOE)将占据苹果MacBook显示面板供应量的51%。苹果的MacBook系列以其最先进的LCD显示面板而著称,其具备高分辨率、氧化物背板、Mini LED背光和低功耗等特性。笔记本电脑厂商也计划在未来几年内从LCD过渡到OLED。 本新闻稿包含多媒体。此处查看新闻稿全文: https://www.businesswire.com/news/h...

0评论2025-07-081539

威兹航空在全球主要航空公司碳排放量排名中位居榜首
全球领先的航空数据分析公司Cirium(睿思誉)推出了全新透明化航空公司二氧化碳排放标准及排名体系,旨在识别各细分领域中表现最佳的航空公司。 伦敦--(美国商业资讯)-- Cirium(睿思誉)近日发布的全球航空公司碳排放最新排名中,威兹航空(Wizz Air)荣登榜首,成为全球最节能减排的航空公司。《Cirium(睿思誉)航班碳排放评估》(The Cirium Flight Emissions Review)报告通过统一且权威的排放基准,对全球前20大航空公司进行了排名。 本新闻稿包含多...

0评论2025-07-081785

华尔街著名公司治理研究与股东投票独立咨询机构Glass Lewis建议科兴股东投票支持现任董事会
Glass Lewis结论:“现任董事会在恢复公司治理稳定和运营正常化方面值得信赖。 [...] 反观异议股东【赛富投资基金】及异议投资者【尚珹资本,维梧资本】的提议反复无常,且提名董事候选人包括与公司过去治理失败有关人士,令人质疑其公信力与解决问题的能力。 科兴现任董事会呼吁广大股东采纳Glass Lewis的建议,在白色委托书投票卡上投下“反对”票,抵制旨在罢免现任董事会并任命“重组”前董事会成员的误导性提案。 科兴控股股东特别会议将于2025年7月8日召开。 详情请访问:VoteSi...

0评论2025-07-081322

Imperva Application Security集成API检测与响应功能,树立API安全新标准
首个统一的单一管理平台,可实时检测和应对API威胁,包括对象级授权失效(BOLA)及其他高级业务逻辑威胁 支持云端和本地环境的灵活部署,采用隐私优先设计,实现大规模API安全防护。 法国默东--(美国商业资讯)--近日,泰雷兹宣布,Imperva Application Security平台新增检测与响应功能,以抵御业务逻辑攻击,例如OWASP十大API安全风险中的首要威胁——对象级授权失效(BOLA)。通过将实时检测与风险API、BOLA攻击、未认证API和弃用...

0评论2025-07-081498

Omdia:Nintendo Switch 2将推动2025年游戏机显示屏出货量激增200%,激发面板技术创新
伦敦--(美国商业资讯)--根据Omdia工业与公共显示及原始设备制造商研究服务报告,2024年全球工业显示面板出货量达2.811亿台,预计2025年将同比增长3.4%至2.906亿台。这一增长主要归因于“智能家居与办公”领域,该领域今年占总出货量的64%。此轮增长的关键因素是最新推出的Nintendo Switch 2,其配备7.9英寸低温多晶硅(LTPS)游戏机显示屏。Omdia预计,2025年游戏机显示屏出货量将突破1500万台,同比涨幅达200%。 本新闻...

0评论2025-07-081902

KIOXIA AiSAQ软件推出新版本向量搜索库,推动AI检索增强生成技术发展
全新开源软件支持根据用户需求与环境灵活平衡容量和性能 东京--(美国商业资讯)--为持续优化固态硬盘(SSD)的使用,提升检索增强生成(RAG)系统中AI向量数据库搜索的可用性,全球存储解决方案领导者Kioxia Corporation今日宣布更新其KIOXIA AiSAQ™(全存储型乘积量化近似最近邻搜索)软件。此次新开源版本引入了灵活控制功能,使系统架构师能够在搜索性能与向量数量之间定义平衡点——这两个因素在系统SSD存储的固定容量中相互制约。这一成果带...

0评论2025-07-071125

诺为泰荣获Frost & Sullivan“2025年全球生物技术CRO公司奖”
澳大利亚悉尼--(美国商业资讯)--凭借卓越的创新能力、客户服务以及国际影响力,Novotech(诺为泰)荣获弗若斯特沙利文 (Frost & Sullivan,简称“沙利文”) 颁发的“2025年全球生物技术CRO公司奖”( 2025 Global Biotechnology Contract Research Organization (CRO) Company of the Year)。 本新闻稿包含多媒体。此处查看新闻稿全文...

0评论2025-07-071267

Pickering Interfaces推出全新高速PXI旋转变压器仿真模块
精准赋能航空航天与汽车行业伺服系统测试全新PXI与PXIe仿真模块支持高达130,000转/分钟的旋转速度,满足新一代伺服系统测试需求 英国克拉克顿海滨--(美国商业资讯)--模块化信号切换与仿真解决方案全球领先供应商 Pickering Interfaces 今日宣布,旗下广受欢迎的PXI(41-670)与PXIe(43-670)系列LVDT、RVDT及旋转变压器仿真模块现已全面升级,支持高达130,000转/分钟的高速旋转变压器仿真,旨在满足航空航天、汽车及国防等关键行业对高性能伺服系统测...

0评论2025-07-071071

ISDA和Ant International牵头撰写关于“守护者计划”下代币化银行负债用于外汇结算和跨境支付的新行业报告
该报告基于共享账本技术以及共同牵头方和“守护者计划”外汇工作组成员的行业专业知识编写而成 报告包含了关于利用代币化银行负债和共享账本的建议原则,以推动行业对代币化的采用,实现全天候实时外汇结算,并为全球企业降低成本 新加坡--(美国商业资讯)--国际互换与衍生品协会(ISDA)和Ant International牵头“守护者计划”(Project Guardian)外汇行业小组,撰写了一份关于在跨境支付和外汇结算中实施代币化银行负债和共享账本的新报告。 本新闻...

0评论2025-07-071057

Venture Global宣布与PETRONAS签署20年购销协议
弗吉尼亚州阿灵顿--(美国商业资讯)-- Venture Global, Inc. (NYSE: VG)今日宣布,与马来西亚国有石油天然气公司PETRONAS的子公司PETRONAS LNG Ltd. (PLL)签署一份新的20年期购销协议(SPA)。根据协议条款,PETRONAS将在20年内每年从Venture Global的第三个设施CP2 LNG每年采购100万吨液化天然气(LNG)。这是对Venture Global与PETRONAS关于每年从Plaquemines LNG设施采购1...

0评论2025-07-071425